Publication: 2054

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)
      QxMD      Google Scholar   
Citation:
Leuk Lymphoma vol 56 (4) 958-964
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
813 is parent abstract
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
40   600   811   813  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA032291, CA33601, U10 CA077658, U10 CA045808, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA077597, U10 CA045418, U10 CA077440, U10 CA041287, U10 CA180833, U10 CA047642, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                 
Networks:
 
Study
CALGB-50501
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
mantle cell lymphoma, bortezomib, lenalidomide